Moderate-intensity statin and ezetimibe aid compliance in elderly atherosclerotic patients: Analysis of RACING Trial Medha Baranwal25 April 2023 9:45 AM ISTKorea: Combination therapy with a moderate-intensity statin plus ezetimibe imparts similar cardiovascular (CV) benefits as standard high-dose statin...
Exercise improve arterial stiffness and benefits in ACVD Aditi19 April 2023 9:15 AM ISTA Systematic review entitled "Comparative effectiveness of different types of exercise in reducing arterial stiffness in children and adolescents: a...
High Lp (a), the key driver for CVD and aortic valve stenosis regardless of CRP levels Medha Baranwal16 March 2023 9:45 AM ISTDenmark: A new study has shown that lowering lipoprotein(a) has potential benefits irrespective of the presence or absence of low-grade systemic...
Lipid-lowering drugs impart cardiovascular benefits across all ethnicities and regions: Study Dr. Kamal Kant Kohli28 Feb 2023 9:30 AM ISTAustralia: Regional and ethnic minority groups derive at least as much cardiovascular benefit as majority groups from lipid-lowering therapies,...
Achieving very low LDL-C tied to lower risk of MI, stroke, and death with no safety concerns: FOURIER-OLE analysis Medha Baranwal16 Feb 2023 10:45 AM ISTUSA: Long-term achievement of lower LDL-C levels, down to <20 mg/dL, is associated with a reduced risk of cardiovascular (CV) outcomes and no...
Medical Bulletin 17/January/2023 Isra Zaman17 Jan 2023 2:30 PM ISTHere are the top medical news for the day:Study finds ChatGPT can write medical research abstracts that can trick scientistsIn a recent study,...
p53 mutation contributes to the development of atherosclerotic cardiovascular disease: Study Isra Zaman17 Jan 2023 9:30 AM ISTIn the new study, published in Nature Cardiovascular Research, the CNIC group led by Jose Javier Fuster demonstrates that p53 mutations also...
Ezetimibe with Statins well tolerated in diabetic patients against CVD Jacinthlyn Sylvia2 Jan 2023 10:15 AM ISTPatients with diabetes mellitus (DM) in the RACING trial population tolerated the effects of ezetimibe and moderate-intensity statin combination...
Even mild liver disease may hamper heart health, finds Cedars-Sinai study Isra Zaman10 Dec 2022 9:15 AM ISTEarlier this year, the American Heart Association (AHA) released a statement that nonalcoholic fatty liver disease-an increasingly common liver...
Early initiation of SGLT2 inhibitors reduces MACE in Type 2 Diabetes patients at ASCVD risk Aditi29 Nov 2022 12:15 PM ISTChina: An investigation has revealed that initiation of SGLT2 inhibitor early in Type 2 Diabetes (T2D) patients reduces the rates of major adverse...
Inclisiran safely reduces LDL-C in primary prevention patients with elevated levels: Study Medha Baranwal19 Nov 2022 11:45 AM ISTTwice-yearly maintenance dosing with inclisiran significantly reduces LDL-C and other atherogenic lipoprotein measurements in patients without...
Olpasiran markedly reduces lipoprotein(a) in atherosclerotic cardiovascular disease: NEJM Dr. Manav Aggarwal7 Nov 2022 8:00 PM ISTUSA: In patients with established atherosclerotic cardiovascular disease (ASCVD), olpasiran treatment remarkably reduced lipoprotein(a)...
